Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
May 30 2023 - 07:00AM
Business Wire
- Abstract published online in the Journal of Clinical
Oncology supplement of the 2023 ASCO Annual Meeting
Proceedings
- Can-Fite to initiate Phase 2a pancreatic cancer
study
- Namodenoson significantly inhibits growth of pancreatic
carcinoma as a stand-alone treatment and in combination with
gemcitabine
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address oncology, inflammatory and liver
diseases, today announced that its study titled “Effects of
Namodenoson on Pancreatic Carcinoma: Preclinical Evidence” is
published online in the Journal of Clinical Oncology supplement of
the 2023 ASCO Annual Meeting Proceedings. The abstract can be read
here: LINK
The pre-clinical study used advanced pancreatic carcinoma
patient cells that were treated with Namodenoson as a stand-alone
and in combination with gemcitabine, the leading chemotherapy used
to treat pancreatic cancer.
A significant dose-dependent inhibition of pancreatic cancer
cell growth was found when the cells were exposed to Namodenoson.
The combined treatment with Namodenoson plus gemcitabine had an
additive inhibitory effect. The molecular mechanism of action,
downregulation of the Wnt signaling pathway, is known to be active
in pancreatic cancer and also reflects the well-established
mechanism of action of Can-Fite’s small molecule drug platform.
Can-Fite plans to initiate an open-label Phase 2a exploratory
trial to assess the efficacy and safety of Namodenoson in the
treatment of patients with pancreatic cancer who have received at
least one previous systemic therapy. Safety and efficacy endpoints
including objective response, progression-free survival, duration
of response, disease control, and overall survival will be
monitored. The study will be conducted by Dr. Salomon Stemmer, an
oncology key opinion leader and Professor at the Institute of
Oncology, Rabin Medical Center, Israel.
“These encouraging results in pancreatic cancer are very much in
line with our findings for Namodenoson in advanced liver cancer
clinical trials,” stated Can-Fite CEO Dr. Pnina Fishman. “We are
pleased to have these data shared through ASCO’s annual meeting,
where we expect it will get high visibility with leading
oncologists focused on pancreatic cancer as well as potential
research and development partners as we head into our exploratory
Phase 2a study.”
About Pancreatic Cancer
The highest incidence rates for pancreatic cancer are in Asia,
Europe, and North America. According to the American Society of
Clinical Oncology (ASCO), in 2020, an estimated 496,000 people were
diagnosed with pancreatic cancer globally and an estimated 466,000
died from the disease. The 5-year survival rate for people with
pancreatic cancer in the U.S. is 11%. Acumen Research estimates the
global pancreatic cancer therapeutics market was valued at
approximately $3.6 billion in 2021 and is projected to grow to
approximately $6.6 billion by 2030.
About Namodenoson
Namodenoson was evaluated in Phase II trials for two
indications, as a second line treatment for hepatocellular
carcinoma (HCC), and as a treatment for non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It is
currently in a Phase IIb trial for NASH and a pivotal Phase III for
HCC. Namodenoson is a small orally bioavailable drug that binds
with high affinity and selectivity to the A3 adenosine receptor
(A3AR). A3AR is highly expressed in diseased cells whereas low
expression is found in normal cells. This differential effect
accounts for the excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, and inflammatory disease. The
Company's lead drug candidate, Piclidenoson recently reported
topline results in a Phase III trial for psoriasis. Can-Fite's
liver drug, Namodenoson, is being evaluated in a Phase IIb trial
for the treatment of non-alcoholic steatohepatitis (NASH), and
enrollment is expected to commence in a Phase III trial for
hepatocellular carcinoma (HCC), the most common form of liver
cancer. Namodenoson has been granted Orphan Drug Designation in the
U.S. and Europe and Fast Track Designation as a second line
treatment for HCC by the U.S. Food and Drug Administration.
Namodenoson has also shown proof of concept to potentially treat
other cancers including colon, prostate, and melanoma. CF602, the
Company's third drug candidate, has shown efficacy in the treatment
of erectile dysfunction. These drugs have an excellent safety
profile with experience in over 1,500 patients in clinical studies
to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial
condition, results of operations, strategies or prospects. All
statements in this communication, other than those relating to
historical facts, are “forward looking statements”. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters.
Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made.
Because forward-looking statements relate to matters that have not
yet occurred, these statements are inherently subject to known and
unknown risks, uncertainties and other factors that may cause
Can-Fite’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Important factors that could cause actual results,
performance or achievements to differ materially from those
anticipated in these forward-looking statements include, among
other things, our history of losses and needs for additional
capital to fund our operations and our inability to obtain
additional capital on acceptable terms, or at all; uncertainties of
cash flows and inability to meet working capital needs; the
initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into
clinical trials or to successfully complete our preclinical studies
or clinical trials; our receipt of regulatory approvals for our
product candidates, and the timing of other regulatory filings and
approvals; the clinical development, commercialization and market
acceptance of our product candidates; our ability to establish and
maintain strategic partnerships and other corporate collaborations;
the implementation of our business model and strategic plans for
our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our
business without infringing the intellectual property rights of
others; competitive companies, technologies and our industry; risks
related to the COVID-19 pandemic and the Russian invasion of
Ukraine; risks related to not satisfying the continued listing
requirements of NYSE American; and statements as to the impact of
the political and security situation in Israel on our business.
More information on these risks, uncertainties and other factors is
included from time to time in the “Risk Factors” section of
Can-Fite’s Annual Report on Form 20-F filed with the SEC on March
30, 2023 and other public reports filed with the SEC and in its
periodic filings with the TASE. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Can-Fite
undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230530005167/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Sep 2023 to Oct 2023
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Oct 2022 to Oct 2023
